Technology

An overview of the advantages of implementing AI into clinical development and the obstacles that prevent its widespread adoption.

Gathering hard evidence on the benefits and risks of DCT solutions.

In the final part of this video interview, Jim Murphy, CEO of Greenphire discusses the role of artificial intelligence, using trusted data, and simplifying protocols.

In the fifth and final part of this video interview, Melissa Easy, VP commercial, digital products & solutions, IQVIA shares what excites her most about the future of clinical technology.

In part 4 of this video interview, Melissa Easy, VP commercial, digital products & solutions, IQVIA highlights how the regulators are addressing new technology with updated guidances.

In part 3 of this video interview, Melissa Easy, VP commercial, digital products & solutions, IQVIA touches on how the right technology for your study should alleviate site burden and improve data quality.

In part 2 of this video interview, Melissa Easy, VP commercial, digital products & solutions, IQVIA discusses how advancements in technology are creating challenges with integration and how they can be addressed.

Q&A with Joachim Lövin explores the challenges and lessons learned in boosting the flexibility of conducting decentralized clinical trials post-COVID.

In part 1 of this video interview, Melissa Easy, VP commercial, digital products & solutions, IQVIA highlights how patients, sites, and sponsors can benefit from recent advancements such as AI and LLMs.

In the fourth and final part of this video interview, Vincent Keunen, founder & CEO of Andaman7 looks forward and highlights some potential advancements with the use of AI.

In part 3 of this video interview, Vincent Keunen, founder & CEO of Andaman7 shares his own experience as a patient when it comes to using digital applications.

In part 2 of this video interview, Vincent Keunen, founder & CEO of Andaman7 highlights how technology vendors should be keeping the patient in mind when building solutions.

Wearables have great potential to continue advancing research in Rett syndrome as well as other rare disease areas.

How artificial intelligence can aid in selecting patients, leveraging safety insights, and optimizing combination therapies.

Despite limitations to its widespread use within healthcare, there is great potential for ChatGPT’s application in drug development.

Panna Sharma, CEO of Lantern Pharma, discusses LP-284, using their RADR during testing, ensuring global use, and what the future holds.

A survey conducted at this year’s Pistoia Alliance conference determined that although 70% of life sciences experts acknowledge artificial intelligence’s potential, many still struggle with its initiation and implementation.

Despite the significance offered by AI to pharmaceutical companies, there are several challenges that must be overcome for successful integration of tech-based tools.